tesamorelin

the FDA-approved injection that targets visceral fat. the dangerous kind.

tier S · weight loss · 15-18% VAT reduction

verdict

the only adult-labeled GHRH analog. FDA-approved for visceral fat reduction in HIV-associated lipodystrophy. the label says it's not a weight-loss drug.

if you're asking whether tesamorelin reduces visceral fat — yes, in the population the trials studied. pooled phase 3 (n=816) showed 15-18% VAT reduction at 26 weeks, CT-measured. subcutaneous fat did not move. mechanism is clean: GHRH triggers a GH pulse, the GH tells the liver to make IGF-1, IGF-1 mobilizes visceral fat.

if you're asking about it for general body recomp — the Egrifta label is explicit that this is not a weight-loss drug. peptide clinics extrapolate the visceral-fat story to general body recomp; the evidence base is HIV-derived. the molecule does what the trials showed for the population the trials studied. that's the bar.

if you came in worried about IGF-1 and cancer risk — IGF-1 roughly doubles on therapy. the label carries precautions around diabetes and IGF-1 monitoring, not cancer. trials ran 26 to 52 weeks. the multi-year cycling pattern at anti-aging clinics is outside what was studied; that's a gap, not a verdict.

based on published evidence and disclosed clinical practice. not medical advice. dose and protocol conversations belong with a clinician.

why S-tier

different mechanism than GLP-1s. tesa tells your pituitary to pulse growth hormone, which mobilizes visceral fat. clean, targeted, documented. FDA-approved since 2010 for HIV-associated lipodystrophy. long-term cardiovascular safety still uncertain. increasingly used off-label by men 40+ for body recomp. S because drug-tier human trial data exists. narrow indication and high cost keep it niche.

the core tension

The only GHRH analog that ever cleared full FDA approval. Indication is narrow by design: HIV-associated visceral fat. Mechanism plausibly extends beyond that population. Direct non-HIV trials are still missing. Clean targeting, real label data, and a much wider off-label story.

what it is

A 44-amino-acid analog of growth hormone-releasing hormone (GHRH). A trans-3-hexenoyl group on the N-terminus blocks DPP-4 cleavage and gives it a usable half-life. Theratechnologies sells it as Egrifta (2010), Egrifta SV (2014), and Egrifta WR (March 2025), all for HIV-associated lipodystrophy. The only GHRH analog with a full FDA approval.

what it does

Tells the pituitary to pulse growth hormone. The GH tells the liver to make IGF-1. IGF-1 mobilizes visceral fat. Pooled phase 3 trials (n=816) showed 15-18% visceral fat reduction at 26 weeks, CT-measured. Subcutaneous fat did not move. Hepatic fat dropped too. Newer data points at neurocognitive outcomes in people with HIV.

origin

Theratechnologies, a Montreal biotech with a market cap under $250 million. Tesa is the whole business. FDA approved November 2010 for HIV-associated lipodystrophy, still the only approved indication. Egrifta WR launched September 2025 with weekly reconstitution and half the injection volume. No generic. Orphan-drug economics keep one out.

why researchers are interested

Visceral fat is the kind that kills you, the deep abdominal fat tied to cardiovascular risk and insulin resistance. Tesa mobilizes it selectively in the population it was studied in. Peptide clinics extrapolate to general body recomp. The longevity crowd treats it as the smarter alternative to direct HGH because it preserves the natural pulse rhythm.

does it work

Yes, for visceral fat. Phase 3 evidence is solid. Mechanism is clean. The 2010 approval has held 15+ years. The label says, in print, it is not for weight loss and long-term cardiovascular safety is unknown. Both worth taking seriously. IGF-1 roughly doubles and needs monitoring. Trials ran 26-52 weeks. The multi-year cycling pattern at peptide clinics is not what was studied. For visceral fat, this is the cleanest tool available. For general weight loss, the wrong drug.

claims vs the data

• reduces visceral abdominal fat — supported — phase III trials n=816: 15-18% VAT reduction at 26 weeks vs placebo. CT-measured.
• doesn't affect subcutaneous fat — supported — selective visceral effect documented across all pivotal trials. not a general weight loss drug.
• raises IGF-1 and growth hormone naturally — supported — labeled mechanism. elevated IGF-1 is part of the effect, and also a monitored safety concern.
• anti-aging for men over 40 — weak — no trials in this population. used off-label based on mechanism reasoning, not evidence.
• safer than HGH injection — partially true — stimulates endogenous GH vs injecting exogenous GH. more physiologic rhythm. but IGF-1 elevation carries similar theoretical risks.
• safe long-term (10+ years) — unverified — label notes "long-term cardiovascular safety is not known." trials were 26-52 weeks.
• works for weight loss generally — contradicted — FDA label specifically states "NOT for weight loss management." works on visceral fat only.
• tesamorelin is a general weight-loss drug — contradicted — The label and trials support reduction of excess abdominal visceral fat in HIV-associated lipodystrophy. The label also says it is not indicated for weight-loss management and that long-term cardiovascular safety has not been established.

key facts

• molecular formula: C₂₂₁H₃₆₆N₆₈O₆₇S
• molecular weight: 5135.8 g/mol
• amino acids: 44
• half-life: ~26-38 minutes (subQ)
• type: GHRH analog (growth hormone-releasing factor)
• CAS: 901758-09-6
• ~15-18% visceral fat reduction
• 2010 FDA approval (egrifta)
• $37,500 annual cost (brand)
• 1 approved indication (HIV lipo)

frequently asked questions

What is tesamorelin?

Tesamorelin is a stabilized analog of growth hormone-releasing hormone (GHRH), FDA-approved as Egrifta for reducing abdominal fat in HIV-associated lipodystrophy. It stimulates pulsatile GH release from the pituitary gland.

What does tesamorelin do?

Tesamorelin stimulates endogenous growth hormone release via GHRH receptor activation, producing the downstream IGF-1 response that mediates GH effects. Clinical trials show visceral fat reduction in HIV-lipodystrophy patients. General body-composition and anti-aging use is an off-label extrapolation from that narrower record.

How is tesamorelin typically administered?

FDA-labeled tesamorelin dosing depends on formulation: Egrifta WR is 1.28 mg once daily, Egrifta SV is 1.4 mg once daily, and the pivotal trial dose was 2 mg daily. All are for excess abdominal fat in HIV-associated lipodystrophy, not general weight loss.

What are the side effects of tesamorelin?

Common side effects include injection-site reactions, joint pain, peripheral edema, and carpal tunnel-like symptoms related to increased GH/IGF-1 signaling. Fasting glucose increases have been observed in trials, and the Egrifta label flags glucose monitoring and a diabetes precaution for the studied population.

Is tesamorelin FDA approved?

Yes. Tesamorelin is FDA-approved as Egrifta for HIV-associated lipodystrophy (2010). Off-label use for general GH stimulation is widespread but unapproved by the FDA.

How much does tesamorelin cost?

Branded Egrifta retails for approximately $3000-4000 per month without insurance, reflecting orphan-drug pricing in the narrow HIV-lipodystrophy indication. On the research-chemical market it sells for a small fraction of the branded-drug price.

related peptides

• sermorelin — original GHRH analog, short half-life
• cjc-1295 — cousin, longer half-life, no FDA approval
• ipamorelin — GHRP, different mechanism, often stacked
• hgh — what it indirectly stimulates

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.